Correlation between Base-Excision Repair Gene Polymorphisms and Levels of In-Vitro BPDE–Induced DNA Adducts in Cultured Peripheral Blood Lymphocytes

Hongping Yu1,2*, Hui Zhao2, Li-E Wang2, Zhensheng Liu2, Donghui Li3, Qingyi Wei2*

1 Department of Epidemiology and Biostatistics, School of Public Health, Guilin Medical University, Guilin, China, 2 Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America, 3 Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America

Abstract

In vitro benzo[a]pyrene diol epoxide (BPDE)-induced DNA adducts in cultured peripheral lymphocytes have been shown to be a phenotypic biomarker of individual’s DNA repair phenotype that is associated with cancer risk. In this study, we explored associations between genotypes of base-excision repair genes (PARP1 Val762Ala, APEX1 Asp148Glu, and XRCC1 Arg399Gln) and in vitro BPDE-induced DNA adducts in cultured peripheral blood lymphocytes in 706 cancer-free non-Hispanic white subjects. We found that levels of BPDE-induced DNA adducts were significantly higher in ever smokers than in never smokers and that individuals with the Glu variant genotypes (i.e., Asp/Glu and Glu/Glu) exhibited lower levels of BPDE-induced DNA adducts than did individuals with the common Asp/Asp homozygous genotype (median RAL levels: 32.0 for Asp/Asp, 27.0 for Asp/Glu, and 17.0 for Glu/Glu, respectively; \( P_{\text{trend}} = 0.030 \)). Further stratified analysis showed that compared with individuals with the common APEX1-148 homozygous Asp/Asp genotype, individuals with the APEX1-148Glu/Glu genotype had a lower risk of having higher-level adducts (adjusted OR = 0.47, 95% CI: 0.26–0.86, respectively; \( P_{\text{trend}} = 0.012 \)) among smokers. Such an effect was not observed in non-smokers. However, there was no significant interaction between the APEX1 Asp148Glu polymorphism and smoking exposure in this study population (\( P = 0.512 \)). Additional genotype-phenotype analysis found that the APEX1-148Glu allele had significantly increased expression of APEX1 mRNA in 270 Epstein-Barr virus-transformed lymphoblastoid cell lines, which is likely associated with more active repair activity. Our findings suggest that the functional APEX1-148Glu allele is associated with reduced risk of having high levels of BPDE-induced DNA adducts mediated with high levels of mRNA expression.

Introduction

Genomic instability plays an important role in the development of cancer, as DNA is frequently damaged by both endogenous metabolites and exogenous carcinogens, such as polycyclic aromatic hydrocarbons (PAHs) occurring in many combustion products. Benzo[a]pyrene (B[a]P) is one of the major PAHs and considered the most carcinogenic, which is metabolized in humans to its ultimate carcinogenic form of benzo[a]pyrene-7,8-dihydriodiol-9,10-epoxide (BPDE). It is known that BPDE can damage DNA by forming DNA adducts through covalent binding to DNA bases [1]. If not repaired, such BPDE-DNA adducts can lead to DNA lesions, such as bulky chemical adducts, ultra violet induced pyrimidine dimers [2], and interstrand cross-links [3,4,5], whereas BER is critically involved in the repair of damaged bases induced by reactive oxygen species, alkylation or ionizing radiation as well as a variety of other lesions, including deaminated base and DNA single strand breaks [6]. For example, inactivation of BER core proteins in mice leads to embryonic lethality, highlighting the vital importance of BER [7].

A number of proteins are involved in the BER process [8,9], of which poly (ADP-ribose) polymerase 1 (PARP1), X-ray repair cross-complementing group 1 (XRCC1) and apurinic/apyrimidinic endonuclease/redox effector-1 (APEX1/Ref-1) play important roles. For example, APEX1 processes the apurinic and apyrimidinic (AP) sites left from the incision of the damaged base by cleaving the 5’phosphodiestere bone, thereby generating a nick with 5’-sugar phosphate and 3’-hydroxyl group. PARP1 specifically binds to DNA strand breaks and plays a role in the long-patch repair process; and XRCC1 interacts with a complex of DNA repair proteins, including poly (ADP-ribose) polymerase, DNA ligase 3, and DNA polymerase β, and coordinates the gap-sealing process in the short-patch BER.
Most BER genes are polymorphic, and some single nucleotide polymorphisms (SNP) have been studied in their associations with risk of various human cancers [2,10,11,12,13,14,15,16]. The possible underlying biological mechanism for the observed associations between these SNPs and cancer risk is that these genetic variants may alter the functional properties of DNA repair enzymes, thereby resulting in alternations in the DNA repair phenotype. Bulky BPDE-DNA adducts are mainly repaired by NER in mammals. We previously showed that SNPs in the NER genes ERCC1 and ERCC2/XPD may modulate levels of the in vitro BPDE-induced DNA adducts in lymphocytes from healthy non-Hispanic whites [17]. However, it remains unknown whether NER is the exclusive repair mechanism for BPDE-adducts, because a fraction of BPDE-adducts were also removed from cellular DNA in xeroderma pigmentosum complementation group A (XPA) cells treated with BPDE, suggesting that other repair mechanisms independent of NER may also be involved in repair of BPDE-induced DNA lesions [18,19,20,21,22].

It has been reported that that some minor BPDE-adducts, such as BPDE-N\textsuperscript{2}-dG adducts and BPDE-N\textsuperscript{3}-dG adducts, may lead to the formation of AP sites and thus elicit the involvement of the BER pathway, suggesting that the BER pathway may also play a role in repairing BPDE-DNA adducts [18]. A previous study found that poly(ADP-ribosylation), which is catalyzes by PARP1, is involved in repair of BPDE-induced DNA lesions [23]. Therefore, we hypothesized that functional SNPs of three major BER genes, \textit{XRCC1}, \textit{APEX1}, and \textit{PARP1}, may be associated with levels of the in vitro BPDE-induced DNA adducts in cultured peripheral lymphocytes of healthy people. Therefore, we used data available from a previously completed case-control study to correlate the levels of the in vitro BPDE-induced DNA adducts and genotypes of these SNPs in BER genes.

Materials and Methods

Study Participants

This study consisted of 706 cancer-free healthy non-Hispanic whites who participated in a previously completed case-control study of squamous cell carcinoma of the head and neck at The University of Texas M. D. Anderson Cancer Center (Houston, TX) [17]. These subjects had been recruited between 1995 and 2005, and were genetically unrelated visitors or companions of patients seen at M. D. Anderson Cancer Center. Self-reported risk behaviors, such as smoking, alcohol drinking as well as demographic information were collected by using questionnaires. After having signed a written informed consent, each participant donated a one-time sample of 30-mL blood that was used for extraction of DNA for genotyping and cell culture of the lymphocytes. The research protocol was approved by The University of Texas M. D. Anderson Cancer Institutional Review Board.

Cell Culture, BPDE Treatment, Measurement of DNA Adducts, and Genotyping

The detailed methods used to determine the in vitro BPDE-induced DNA adducts levels in these study participants have been described elsewhere [24,25]. Briefly, one ml of the whole blood from each participant was cultured in each of two T-25 flasks (each containing 9 ml of standard RPMI 1640 supplemented with 15% fetal bovine serum and 112.5 μg/ml phytohemagglutinin). After 67 h of phytohemagglutinin stimulation, BPDE was added to the culture to a final concentration of 4 μmol/L, and lymphocytes for performing the assay were harvested after another 5 h incubation. The induced BPDE-DNA adducts were detected by \textsuperscript{32}P postlabeling and quantified by the relative adduct labeling (RAL) per 10\textsuperscript{7} nucleotides. The genomic DNA samples were used for genotyping of three common, well-studied SNPs: \textit{XRCC1} Arg399Gln (rs25487), \textit{PARP1} Val762Ala (rs1136410), and \textit{APEX1} Asp148Glu (rs1130409). These SNPs are potentially functional, because they cause non-synonymous amino acid changes and have been reported to be associated with cancer risk [13,14,16,26,27,28,29,30]. Detailed genotyping methods have been described elsewhere [2].

Correlation between Polymorphisms and Gene Expression Levels

The genotyping data were derived from the HapMap Phase II release 23 data set consisting of 3.96 million SNP genotypes from 270 HapMap individuals [90 Utah residents with ancestry from northern and western Europe (CEU), 45 Han Chinese in Beijing, China (CHB), 45 Japanese in Tokyo, Japan (JPT), and 90 Yoruba in Ibadan, Nigeria (YRI)] [31]. The gene expression (mRNA levels) data by the genotypes of SNPs in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines were derived from the same 270 HapMap individuals and are publicly available online (http://app3.titan.uio.no/biotools/help.php?app = snpexp) [32,33]. Student’s test was used to compare differences in mRNA expression levels between two different genotypes, and the linear trend of mRNA expression levels among genotypes (0, 1 and 2 variant alleles) was tested using linear regression models.

Statistical Analysis

The deviation of the genotype distributions from Hardy-Weinberg equilibrium was tested by a chi-square goodness-of-fit test. A non-parametric Wilcoxon two-sample test or non-parametric analysis of variance \(F\) test was used to determine differences in DNA adduct distributions by categorical variables, such as age, sex, smoking status, alcohol consumption, family history of cancer and genotypes. The linear trend of DNA adduct values was tested in variables with more than two categories using linear regression models. Levels of DNA adducts were also dichotomized by the median to calculate odds ratios (ORs) and their 95% confidence intervals (CIs) to estimate their association with genotypes of each selected SNP, levels of DNA adducts greater than the median were classified as high levels, whereas values less than and equal to the median were classified as low levels. All analyses were performed with SAS statistical software (SAS version 9.2; SAS Institute Inc., Cary, NC). All analyses were two sided with a statistical significance set at a \(P\) value of \(<0.05\).

Results

Of the 706 healthy non-Hispanic white subjects with a mean age of 56.1 years (range: 20–85 years old), 182 (25.8%) were women, and 524 (74.2%) were men. There were 122 (17.3%) former drinkers and 294 (41.6%) current drinkers, and the number of former smokers and current smokers was 252 (35.7%) and 123 (17.4%), respectively. The genotype frequencies of the three SNPs among these subjects were all in agreement with the Hardy-Weinberg equilibrium (chi-square test: \(\chi^2 = 2.711, P = 0.110\) for \textit{PARP1} Val762Ala, \(\chi^2 = 0.138, P = 0.710\) for \textit{APEX1} Asp148Glu, and \(\chi^2 = 0.784, P = 0.376\) for \textit{XRCC1} Arg399Gln).

As shown in Table 1, the distribution of the in vitro BPDE-induced DNA adduct levels was not different by sex, age, alcohol drinking, and family history of cancer. However, levels of BPDE-induced DNA adducts were significant higher in ever or current smokers than in never smokers. Because smoking was significantly associated with higher levels of DNA adducts, the correlation between pack-years of smoking and levels of BPDE-induced...
aducts was further assessed, but the correlation was not statistically significant (correlation coefficient (r) = 0.506).

We compared the BPDE-induced DNA adducts by genotypes for PARP1 Val762Ala, APEX1 Asp148Glu and XRCC1 Arg399Gln SNPs. There was a significant genotype-phenotype correlation between the variant APEX1-148Glu allele and levels of BPDE-induced DNA adducts in an allele dose-response manner. Specifically, individuals with the Glu variant genotypes (i.e., Asp/Glu and Glu/Glu) exhibited lower levels of BPDE-induced DNA adducts than did individuals with the common Asp/Asp homozygous genotype (median RAL levels: 26.5). As a result, individuals with high levels of DNA adducts were assumed to have a high DRC, whereas those with low levels of DNA adducts were assumed to have a lower DRC. We then estimated the associations between genotypes of each SNP and levels of BPDE-induced DNA adducts stratified by subgroups of age, sex, smoking/drinking statuses (defined as never, former, current), and family history of cancer, we only found that a lower risk of having higher levels of adducts was observed in smokers, but not in non-smokers, among individuals who had the Asp/Glu or Glu/Glu genotype (Table 3). Compared with individuals with the common APEX1-148 homozygous Asp/Asp genotype, individuals with the APEX1-148Asp/Glu genotype or the Glu/Glu genotype had a lower risk of having higher-level adducts (adjusted OR = 0.60, 95% CI: 0.36–0.98 and adjusted OR = 0.47, 95% CI: 0.26–0.86, respectively; \( P_{\text{trend}} = 0.012 \)) among smokers. However, we found no statistical evidence for an interaction between APEX1 Asp148Glu genotypes and smoking in the multivariate logistic regression model (\( P = 0.512 \) for the interaction term). In addition, the risk of having high levels of BPDE-induced DNA adducts was not statistically significant for the PARP1 Val762Ala and XRCC1 Arg399Gln SNPs (Table 3). No significant difference was observed concerning the age, sex, drinking status and family history of cancer for each SNP (data not shown).

To understand the underlying molecular mechanism of the observed association of the APEX1-148 variant genotypes (Glu/Glu and Asp/Glu) with lower levels of BPDE-induced DNA adducts and decreased risk of cancer, we further assessed the effect of the APEX1 Asp148Glu polymorphism on APEX1 mRNA levels using the APEX1 mRNA expression data in EBV-transformed lymphoblastoid cell lines derived from 270 HapMap individuals and available genotyping data from the same individuals. We found a significant correlation between the APEX1 Asp148Glu genotypes and APEX1 mRNA expression. Individuals with the APEX1-148 Asp/Glu or Glu/Glu genotypes had higher levels of APEX1 expression than those with the APEX1-148 Asp/Asp genotype (Asp/Asp vs. Asp/Glu: \( P = 0.0003 \); Asp/Asp vs. Glu/Glu: \( P = 0.037 \)). Furthermore, the trend test for this increased effect of the number (i.e., 0, 1 and 2) of the APEX1-148 Glu alleles on the APEX1 mRNA expression levels was statistically significant (\( P_{\text{trend}} = 0.002 \)).

\( P_{\text{trend}} \) value was obtained using the Wilcoxon two-sample test for the genotype of one or two copies of the minor allele compared with zero copies of the minor allele in each SNP. 
\( P_{\text{trend}} \) value was obtained using the non-parametric analysis of variance test for the trend among genotypes.

doi:10.1371/journal.pone.0040131.t001

doi:10.1371/journal.pone.0040131.t002

**Table 1.** Distribution of DNA adducts in cultured peripheral lymphocytes from 706 cancer-free non-Hispanic white subjects by selected variables.

| Variable                          | No. (%) | Levels of DNA adducts* | \( P^b \)  | \( P^c \) |
|-----------------------------------|---------|------------------------|------------|------------|
| Total                             | 706 (100) | 26.5                |            |            |
| Age (median, years)               |         |                       |            |            |
| \( \leq 57 \)                     | 377 (53.4) | 26.0                | Reference  | 0.643      |
| \( > 57 \)                       | 329 (46.6) | 27.0                | 0.199      |            |
| Sex                               |         |                       |            |            |
| Female                            | 182 (25.8) | 22.5                | Reference  |            |
| Male                             | 524 (74.2) | 27.5                | 0.086      |            |
| Family history of cancer          |         |                       |            |            |
| No                                | 279 (39.6) | 27.0                | Reference  |            |
| Yes                              | 425 (60.4) | 26.0                |            | 0.806      |
| Drinking status                   |         |                       |            |            |
| Never                            | 290 (41.1) | 26.0                | Reference  |            |
| Former                           | 122 (17.3) | 21.0                | 0.283      | 0.321      |
| Current                          | 294 (41.6) | 29.0                |            | 0.594      |
| Smoking status                    |         |                       |            |            |
| Never                            | 331 (46.9) | 20.0                | Reference  |            |
| Former                           | 252 (35.7) | 31.5                | 0.017      | 0.002      |
| Current                          | 123 (17.4) | 37.0                |            | 0.001      |

*The median level of BPDE-induced DNA adducts.

\( P^b \) value was obtained using the Wilcoxon two-sample test for the genotype of one or two copies of the minor allele compared with zero copies of the minor allele in each SNP.

\( P^c \) value was obtained using the non-parametric analysis of variance test for the trend among genotypes.

doi:10.1371/journal.pone.0040131.t001

**Table 2.** Genotype-phenotype correlation between genotypes of BER SNPs and levels of BPDE-induced-DNA adducts in cultured peripheral lymphocytes from 706 cancer-free non-Hispanic white subjects.

| Genotype | No. (%) | Levels of DNA adducts* | \( P^b \)  | \( P^c \) |
|----------|---------|------------------------|------------|------------|
| PARP1    |         |                       |            |            |
| Val/Val  | 495 (70.1) | 27.0                | Reference  |            |
| Val/Ala  | 185 (26.2) | 24.0                | 0.523      |            |
| Ala/Ala  | 26 (3.7)  | 32.5                | 0.317      | 0.477      |
| APEX1    |         |                       |            |            |
| Asp/Asp  | 201 (28.5) | 32.0                | Reference  |            |
| Asp/Glu  | 356 (50.4) | 27.0                | 0.728      |            |
| Glu/Glu  | 149 (21.1) | 17.0                | 0.015      | 0.030      |
| XRCC1    |         |                       |            |            |
| Arg/Arg  | 291 (41.2) | 28.0                | Reference  |            |
| Arg/Gln  | 316 (44.8) | 27.0                | 0.386      |            |
| Gln/Gln  | 99 (14.0)  | 25.0                | 0.164      | 0.346      |

*The median level of BPDE-induced DNA adducts.

\( P^b \) value was obtained using the Wilcoxon two-sample test for the genotype of one or two copies of the minor allele compared with zero copies of the minor allele in each SNP.

\( P^c \) value was obtained using the non-parametric analysis of variance test for the trend among genotypes.

doi:10.1371/journal.pone.0040131.t002
In 706 healthy non-Hispanic individuals, we investigated associations between three genetic polymorphisms in BER genes (PARP1 Val762Ala, APEX1 Asp148Glu, XRCC1 Arg399Gln) and levels of BPDE-induced DNA adducts measured in cultured peripheral lymphocyte. We found that levels of BPDE-induced DNA adducts were significantly higher in former and current smokers than in never smokers and that APEX1 Asp148Glu, but not PARP1 Val762Ala or XRCC1 Arg399Gln, was associated with levels of the in vitro BPDE-induced DNA adducts. Smokers carrying the APEX1 -148Glu variant genotypes (Glu/Glu and Asp/Glu) had significantly lower levels of BPDE-induced DNA adducts, representing a 2.13-fold or a 1.67-fold decreased risk of having high levels of BPDE-induced DNA adducts compared with those smokers carrying the APEX1-148 homozygous Asp/Asp genotype, respectively. Such an effect was not observed in non-smokers.

These findings were further supported by the results from the correlation analysis between polymorphisms and mRNA expression levels, in which the APEX1 -148Glu variant genotypes were also associated with increased levels of the APEX1 mRNA expression in EBV-transformed lymphoblastoid cell lines derived from 270 HapMap individuals. All these were not found for other two SNPs of PARP1 Val762Ala and XRCC1 Arg399Gln.

The variant allele frequencies of PARP1 Val762Ala, APEX1 Asp148Glu, and XRCC1 Arg399Gln in our study population (0.17, 0.46 and 0.36, respectively) were similar to those (0.15, 0.52, and 0.37, respectively) for 226 Utah residents with Northern and Western European ancestry from the CEPH collection (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36). The variant allele frequencies of these SNPs are also similar to many other studies of Caucasian populations [26,34,35].

The in vitro BPDE-induced DNA adducts have been used as an indirect measure of DRC, in which individuals with high levels of BPDE-DNA adducts were assumed to have a low DRC, while those with low levels of BPDE-DNA adducts had a high DRC [36]. Some evidence indicates that reduced DRC may be associated with an increased risk of cancer [36,37,38,40,41,42,43]. Our finding further indicates that the APEX1 Asp148Glu polymorphism may be functional by altering levels of APEX1 mRNA expression, which is also associated with increased levels of the APEX1 mRNA expression in EBV-transformed lymphoblastoid cell lines derived from 270 HapMap individuals. All these were not found for other two SNPs of PARP1 Val762Ala and XRCC1 Arg399Gln.

### Table 3. Genotype-phenotype association between BER SNPs and BPDE-induced DNA adducts in cultured peripheral lymphocytes from 706 cancer-free non-Hispanic white subjects stratified by smoking status.

| SNP   | Levels of DNA adducts** | Crude OR (95% CI) | Adjusted OR (95% CI) b | *P* trend b |
|-------|-------------------------|-------------------|------------------------|------------|
|       | Crude OR (95% CI)       | Adjusted OR (95% CI) b | *P* trend b |
| **No. (%)** | **No. (%)** | Reference | Reference | 0.522 |
| Never smokers | | Reference | Reference | 0.966 |
| PARP1 | Val/Val | 107 (72.8) | 127 (69.0) | 0.81 (0.49–1.32) | 0.80 (0.48–1.31) |
|       | Val/Ala | 36 (24.5) | 53 (28.8) | 1.19 (0.29–4.86) | 1.14 (0.27–4.83) |
|       | Val/Ala | 4 (2.7) | 4 (2.2) | 1.37 (0.83–2.28) | 1.42 (0.85–2.37) |
| APEX1 | Asp/Asp | 40 (27.2) | 57 (31.0) | 0.86 (0.46–1.62) | 0.91 (0.48–1.74) |
|       | Asp/Glu | 81 (55.1) | 84 (45.7) | 1.15 (0.72–1.84) | 1.16 (0.72–1.85) |
|       | Glu/Glu | 26 (17.7) | 43 (23.4) | 1.37 (0.83–2.28) | 1.42 (0.85–2.37) |
| XRCC1 | Arg/Arg | 57 (38.8) | 76 (41.3) | 0.97 (0.49–1.93) | 0.99 (0.50–1.98) |
|       | Arg/Gln | 71 (48.3) | 82 (44.6) | 1.15 (0.72–1.84) | 1.16 (0.72–1.85) |
|       | Gln/Gln | 19 (12.9) | 26 (14.1) | 0.86 (0.46–1.62) | 0.91 (0.48–1.74) |
| Ever smokers | | Reference | Reference | 0.943 |
| PARP1 | Val/Val | 144 (69.9) | 117 (69.2) | 0.92 (0.58–1.47) | 0.96 (0.60–1.55) |
|       | Val/Ala | 51 (24.8) | 45 (26.6) | 1.28 (0.48–3.40) | 1.16 (0.43–3.17) |
|       | Val/Ala | 11 (5.3) | 7 (4.1) | 1.37 (0.83–2.28) | 1.42 (0.85–2.37) |
| APEX1 | Asp/Asp | 67 (32.5) | 37 (21.9) | 0.97 (0.49–1.93) | 0.99 (0.50–1.98) |
|       | Asp/Glu | 101 (49.0) | 90 (53.3) | 1.50 (0.78–2.91) | 1.47 (0.76–2.86) |
|       | Glu/Glu | 38 (18.4) | 42 (24.9) | 1.50 (0.78–2.91) | 1.47 (0.76–2.86) |
| XRCC1 | Arg/Arg | 89 (43.2) | 69 (40.8) | 0.91 (0.59–1.41) | 0.92 (0.58–1.44) |
|       | Arg/Gln | 88 (42.7) | 75 (44.4) | 0.90 (0.48–1.67) | 0.92 (0.49–1.72) |
|       | Gln/Gln | 29 (14.1) | 25 (14.8) | 0.90 (0.48–1.67) | 0.92 (0.49–1.72) |

aThe median level of BPDE-induced DNA adducts.
bAdjusted for age, gender, pack years, alcohol status, and family history of cancer.
doi:10.1371/journal.pone.0040131.t003

### Discussion

In 706 healthy non-Hispanic individuals, we investigated associations between three genetic polymorphisms in BER genes (PARP1 Val762Ala, APEX1 Asp148Glu, XRCC1 Arg399Gln) and levels of BPDE-induced DNA adducts measured in cultured peripheral lymphocyte. We found that levels of BPDE-induced DNA adducts were significantly higher in former and current smokers than in never smokers and that APEX1 Asp148Glu, but not PARP1 Val762Ala or XRCC1 Arg399Gln, was associated with levels of the in vitro BPDE-induced DNA adducts. Smokers carrying the APEX1-148Glu variant genotypes (Glu/Glu and Asp/Asp) had significantly lower levels of BPDE-induced DNA adducts, representing a 2.13-fold or a 1.67-fold decreased risk of having high levels of BPDE-induced DNA adducts compared with those smokers carrying the APEX1-148 homozygous Asp/Asp genotype, respectively. Such an effect was not observed in non-smokers. These findings were further supported by the results from the correlation analysis between polymorphisms and mRNA expression levels, in which the APEX1-148Glu variant genotypes were also associated with increased levels of the APEX1 mRNA expression in EBV-transformed lymphoblastoid cell lines derived from 270 HapMap individuals. All these were not found for other two SNPs of PARP1 Val762Ala and XRCC1 Arg399Gln.

The variant allele frequencies of PARP1 Val762Ala, APEX1 Asp148Glu, and XRCC1 Arg399Gln in our study population (0.17, 0.46 and 0.36, respectively) were similar to those (0.15, 0.52, and 0.37, respectively) for 226 Utah residents with Northern and Western European ancestry from the CEPH collection (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36). The variant allele frequencies of these SNPs are also similar to many other studies of Caucasian populations [26,34,35].

The in vitro BPDE-induced DNA adducts have been used as an indirect measure of DRC, in which individuals with high levels of BPDE-DNA adducts were assumed to have a low DRC, while those with low levels of BPDE-DNA adducts had a high DRC [36]. Some evidence indicates that reduced DRC may be associated with an increased risk of cancer [36,37,38,40,41,42,43]. Our finding further indicates that the APEX1 Asp148Glu polymorphism may be functional by altering levels of APEX1 mRNA expression, which is also associated with increased levels of the APEX1 mRNA expression in EBV-transformed lymphoblastoid cell lines derived from 270 HapMap individuals. All these were not found for other two SNPs of PARP1 Val762Ala and XRCC1 Arg399Gln.
likely to have an effect on the efficiency of removing the DNA adducts in the host cells. However, this hypothesis needs to be tested in more rigorous functional or mechanistic studies.

There are several lines of evidence supporting an association between the variant APEX1-148 Glu allele and a decreased risk of a number of human cancers. Li et al. reported that APEX1-148 Asp/Glu and Glu/Glu genotypes conferred a 1.67-fold (95% CI: 0.41–0.86) and 1.72-fold (95% CI: 0.38–0.88) decreased risk, respectively, of developing cutaneous melanoma [2]. Matullo et al. found that the APEX1-148Glu allele exhibited a decreased risk (Asp/Glu+Glu/Glu: OR = 0.59, 95% CI = 0.35–0.99) of upper aero-digestive cancer [26]. Shekari et al. reported that the variant genotypes (Glu/Glu and Asp/Glu) were associated with decreased risk of developing of cervix cancer (OR = 0.51, 95% CI = 0.31–0.83) [27]. Deng et al. found that a significant decreased risk of lung squamous cell carcinoma for subjects carrying the Glu/Glu genotype (OR = 0.52, 95% CI = 0.31–0.83) and 1.72-fold (95% CI: 0.38–0.88) decreased risk, respectively, of developing cutaneous melanoma [2]. Matullo et al. found that the APEX1-148Glu allele exhibited a decreased risk (Asp/Glu+Glu/Glu: OR = 0.59, 95% CI = 0.35–0.99) of upper aero-digestive cancer [26]. Shekari et al. reported that the variant genotypes (Glu/Glu and Asp/Glu) were associated with decreased risk of developing of cervix cancer (OR = 0.51, 95% CI = 0.31–0.83) [27]. Deng et al. found that a significant decreased risk of lung squamous cell carcinoma for subjects carrying the Glu/Glu genotype (OR = 0.52, 95% CI = 0.31–0.83) and 1.72-fold (95% CI: 0.38–0.88) decreased risk, respectively, of developing cutaneous melanoma [2]. Matullo et al. found that the APEX1-148Glu allele exhibited a decreased risk (Asp/Glu+Glu/Glu: OR = 0.59, 95% CI = 0.35–0.99) of upper aero-digestive cancer [26]. Shekari et al. reported that the variant genotypes (Glu/Glu and Asp/Glu) were associated with decreased risk of developing of cervix cancer (OR = 0.51, 95% CI = 0.31–0.83) [27].

In this genotype-phenotype association study, we have found a clear association of the APEX1-148 Glu allele with decreased BPDE-induced DNA adducts levels in cultured lymphocytes, which suggests a possible role of the APEX1 gene in repairing bulky BPDE-induced DNA adducts and thus in susceptibility to cancer. Therefore, our finding is biologically plausible. Although BPDE-induced DNA adducts are mainly repaired by NER, BER has also been suggested as another possible pathway for repairing such adducts [18,19]. BPDE, an ultimate carcinogenic form of B[a]P that reacts at several sites of DNA, forming covalently linked adducts [48,49,50]. It has been reported that 80–90% of the total BPDE adducts produced are at the N2 position of guanine, and 10–20% are minor adducts including N7 of guanine, N6 of adenine, and N3 of cytosine [48,51,52,53,54,55,56]. It has been also shown that N2-BPDE-dG adducts, a major type of BPDE-DNA adducts, are primarily repaired by the NER pathway [18,57,58]. However, those minor adducts in DNA may promote depurination [18,51,52,59], generating AP sites that are known to be repaired by BER. For example, Braithwaite and his colleagues examined repair of DNA lesions induced by several PAHs, including BPDE, in a human cell-free system, in which NER was indeed found to be an important mechanism in repairing PAHs-induced DNA adducts; however, they also found that after BPDE treatment some BPDE adducts caused rapid depurination, leaving AP sites in DNA, which could then be repaired by BER as well [18].

APEX1 is a critical enzyme involved in recognition and processing of AP sites in DNA during BER. These mutagenic and cytotoxic AP sites are generated by spontaneous depurination or removal of damaged bases by a DNA glycosylase. APEX1 cleaves the DNA backbone 5’ to an AP site, giving a 3’-OH primer for repair synthesis, and coordinates BER by interacting directly or indirectly with other BER proteins [6,60,61,62]. In addition, APEX1, also named redox factor-1 (Ref-1), functions as

Figure 1. Levels of APEX1 mRNA expression by APEX1 Asp148Glu genotypes in Epstein-Barr virus-transformed lymphoblastoid cell lines derived from 270 Hapmap individuals. Compared with individuals carrying the APEX1-148Asp/Asp genotype, those carrying the APEX1-148Asp/Glu or Glu/Glu genotypes had higher levels of APEX1 mRNA expression (Asp/Asp vs. Asp/Glu: P = 0.0003; Asp/Asp vs. Glu/Glu: P = 0.037). Furthermore, the trend test for this increased effect of the APEX1-148 Glu allele on the APEX1 expression was statistically significant (P trend = 0.002). The box represents the interquartile range, which contains 50% of the values. The lower and the upper edges of the box plot are the first quartile (25th percentile) and the third quartile (75th percentile), respectively. The line across the box indicates the median value. The ends of the vertical lines extend to a maximum of 1.5 times the interquartile. In the box plots outliers are marked as dots, which are more than 1.5-fold the box length away from the upper or lower edge of the box. (One individual’s genotyping data were unavailable.).

doi:10.1371/journal.pone.0040131.g001
a redox co-activator and has been found to regulate gene expression of a number of transcription factors, such as p53 and activator protein-1 (AP-1), hypoxia inducible factor-1 alpha (HIF-1α), and cAMP-response element binding protein (CREB), through both redox-dependent and redox-independent mechanisms [63,64,65]. It is well documented that p53 and AP-1 are rapidly induced in response to a number of cellular stimuli to regulate the expression of several DNA-repair proteins involved in different DNA repair pathways including NER, such as ERCC1, XPA, RAD23B, ERCC3, XPC, and DDB2 [61]. Therefore, APEX1 seems to play an important role in NER as well via interaction with p53 and AP-1. Taken together, our data suggest that APEX1 could be involved in directly/indirectly removing BPDE-DNA adducts.

In the present study, further stratified analyses by smoking for each polymorphism showed that the association between the lower risk of having high levels of the BPDE-induced DNA adducts and the APEX1-148Glu variant genotypes (Glu/Glu and Asp/Glu) was only observed in smokers but not in non-smokers, suggesting a SNP-smoking interaction effect on levels of the BPDE-induced DNA adducts. However, such a modification effect of the APEX1 Asp148Glu polymorphism on the risk for higher levels of the BPDE-induced DNA adducts was not statistically significant. This lack of significance could be due to the small sample size in the subgroups, which may have limited the statistical power to detect such an interaction. Therefore, our finding should be interpreted with caution and needs to be validated in future studies with larger sample sizes.

Some of limitations of our study should be considered. First, only three potentially functional polymorphisms in the selected major genes in the BER pathway were included. Second, because our study only included non-Hispanic white subjects, it is uncertain whether these results are generalizable to other ethnic populations. Third, because of the smaller sample size in certain strata of stratified analysis, random errors could exist. Fourth, differing metabolic capacity of the participants, such as individual variability in metabolizing capacity of Phase II enzymes, could have impacted the adduct levels, whereas, based on our current data, it is unknown whether individual variability in metabolic genes may have an impact on the adduct levels formed in cultured peripheral blood lymphocytes. It would be appropriate to investigate a possible effect of polymorphisms in metabolic genes in modulating the levels of the BPDE-induced DNA adducts in future studies. Finally, the significant correlation between the genotypes and mRNA expression of APEX1, using the data from 270 HapMap individuals including 90 CEU, 45 CHB, 45 JPT, and 90 YRI individuals, disappeared after stratification by ethnic groups. Although the correlation may be biologically plausible, it may not be generalizable to the current study of non-Hispanic white only. It is also possible that small sample size after stratification might limit the statistical power. It would be ideal for us to detect such a correlation in our own samples, but we failed to do so because tissue samples of the participants were unavailable in the current study for which the recruitment was completed years ago. To the best of our knowledge, however, this is the first study to investigate the association between in vitro BPDE-induced adducts and polymorphisms of the BER genes (XRCC1, PARP1, and APEX1), in which the APEX1 Asp148Glu polymorphism was shown to modulate levels of BPDE-induced DNA adducts, suggesting that APEX1 Asp148Glu may be one of the underlying mechanisms for the observed low host’s DRC involved in cancer susceptibility in the general population. Nevertheless, our finding must be confirmed by more rigorous mechanistic studies and subsequent larger epidemiological studies with different ethnic groups.

Acknowledgments

We thank Margaret Lung and Kathryn Patterson for recruiting the study participants, Jianzhong He for processing blood samples and Ping Chang for performing the adduct assays.

Author Contributions

Conceived and designed the experiments: JW, QW. Performed the experiments: DL, ZL. Analyzed the data: HZ, HY. Contributed reagents/materials/analysis tools: QW. Wrote the paper: HY.
DNA bases in the urine of cigarette smokers and women exposed to household coal smoke. Chem Res Toxicol 14: 192–201.

23. Stierum RH, van Herwijnen MH, Hageman GJ, Kleinjans JC (1994) Increased poly(ADP-ribos) polymerase activity during repair of (α,ω−anisyl-benzo[α]pyrene diol epoxide-induced DNA damage in human peripheral blood lymphocytes in vitro. Carcinogenesis 15: 743–751.

24. Li D, Firozi PF, Chang P, Wang LE, Xiong P, et al. (2001) In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of hand and neck. Cancer Res 61: 5630–5634.

25. Matullo G, Dunning AM, Guarnera S, Baynes C, Polidoro S, et al. (2004) DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 25: 997–1007.

26. Shekari M, Sohji RK, Tamanian DM, Malekzadeh K, Kaur P, et al. (2006) Association of genetic polymorphism of the DNA base excision repair gene (APE-1 Asp/148 Glu) and HPV type (16/18) with the risk of cervix cancer in north Indian population. Cancer Biomark 4: 63–71.

27. Deng Q, Sheng L, Su D, Zhang L, Liu P, et al. (2011) Genetic polymorphisms in ATM, ERCC1, APE1 and XAPPP genes and lung cancer risk in a population of southeast China. Med Oncol.

28. Li Z, Guan W, Li MX, Zhong ZY, Qian CY, et al. (2011) Genetic polymorphisms in sporadic breast cancer. Oncol Rep 19: 1033–1038.

29. Matullo G, Dunning AM, Guarnera S, Baynes C, Polidoro S, et al. (2006) DNA repair and susceptibility to basal cell carcinoma: a case-control study. Int J Cancer 58: 179–184.

30. Wei Q, Spitz MR (1996) Reduced DNA repair capacity in lung cancer patients. Cancer Res 56: 4103–4107.

31. Canbay E, Agachan B, Guillot B, Ishir T, Balik E, et al. (2010) Possible associations of APE1 polymorphism with susceptibility and HOOG1 polymorphism with prognosis in gastric cancer. Anticancer Res 30: 1339–1344.

32. De Ruyck K, Szunmukkessed M, De Ruider I, Dehoume A, Vraal A, et al. (2007) Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 631: 101–110.

33. Lo VL, Jou YN, Hsiao CF, Chiang WC, Tsai YH, et al. (2009) A polymorphism in the APE1 gene promoter is associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 18: 223–229.

34. Gergen M, Wilson N, Vassiliou V, Ali M, Narasimhan P, et al. (2010) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27: 560–567.

35. Cheng SC, Hilton BD, Roman JM, Dipple A (1989) DNA adducts from carcinogenic and noncarcinogenic enantiomers of benzo[a]pyrene dihydrodiol epoxide. Chem Res Toxicol 2: 334–340.

36. Weinstein IB, Jeffery AM, Jernette KB, Bobstbin SH, Harvey RG, et al. (1956) Benzo[a]pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo. Science 193: 592–595.

37. Meoehan T, Straub K (1979) Double-stranded DNA stereospecifically binds benzo[a]pyrene diol epoxides. Nature 277: 410–412.

38. Osborne MR, Jacobs S, Harvey RG, Brookes P (1981) Minor products from the reaction of (+) and (-) benzo[a]pyrene-anti-diol epoxide with DNA. Carcinogenesis 2: 533–536.

39. Osborne M, Merrill R (1985) Depurinisation of benzo[a]pyrene-diol epoxide-treated DNA. Chem Biol Interact 53: 183–195.

40. Alexandrov K, Rojas M, Satarug S (2010) The critical DNA damage by benzo[a]pyrene in lung tissues of smokers and approaches to preventing its formation. Toxicol Lett 190: 53–62.

41. Jeffrey AM, Grzeskowiak K, Weinstein IB, Nakaniishi K, Reller P, et al. (1979) Benzo[a]pyrene-7,8-dihydridiol 9,10-oxide adenosine and deoxyadenosine adducts: structure and stereochemistry. Science 206: 1309–1311.

42. Straub KM, Meoehan T, Birlingeume AL, Gerval M (1972) Identification of the major adducts formed by reaction of benzo[a]pyrene diol epoxide with DNA in vitro. Proc Natl Acad Sci U S A 74: 5201–5209.

43. Devaursan PD, Ramakrishna NV, Todorovie R, Ragan E, Cavalleri EL, et al. (1992) Identification and quantitation of benzo[a]pyrene-DNA adducts formed by rat liver microsomes in vitro. Chem Res Toxicol 5: 392–509.

44. Van Houten B (1990) Nucleotide excision repair in Escherichia coli. Microbiol Rev 54: 18–31.

45. Grzeskowiak K, Meoehan T, Guza D, Luneva N, Greadintc NO, Naehed H (1997) Base pair conformation-dependent excision of benzo[a]pyrene diol epoxide-guanine by human nucleotide excision repair enzymes. Mol Cell Bioi 17: 7069–7076.

46. King HW, Osborne MR, Brookes P (1979) The in vitro DNA repair in vivo and in vivo in relation to lung cancer at the N7-position of guanine of the ultimate carcinogen derived from benzo[a]pyrene. Chem Biol Interact 24: 345–353.

47. Liao M, He H, Kelley MR, Georgiadis MM (2007) Relative impact of nucleotide and copy number variation on gene expression phenotype. BMC Bioinformatics 11: 600.

48. Tell G, Quadrifoglio F, Tiribelli C, Uelles MR (2009) The many functions of APE-1 Asp/148 Glu and (-) benzo[a]-pyrene-anti-diolepoxide with DNA. Antioxid Redox Signal 3: 671–683.

49. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.

50. Straub KM, Meoehan T, Burlingeume AL, Gerval M (1972) Identification of the major adducts formed by reaction of benzo[a]pyrene diol epoxide with DNA in vitro. Proc Natl Acad Sci U S A 74: 5201–5209.

51. Devaursan PD, Ramakrishna NV, Todorovie R, Ragan E, Cavalleri EL, et al. (1992) Identification and quantitation of benzo[a]pyrene-DNA adducts formed by rat liver microsomes in vitro. Chem Res Toxicol 5: 392–509.

52. Van Houten B (1990) Nucleotide excision repair in Escherichia coli. Microbiol Rev 54: 18–31.

53. Grzeskowiak K, Meoehan T, Guza D, Luneva N, Greadintc NO, Naehed H (1997) Base pair conformation-dependent excision of benzo[a]pyrene diol epoxide-guanine by human nucleotide excision repair enzymes. Mol Cell Bioi 17: 7069–7076.

54. King HW, Osborne MR, Brookes P (1979) The in vitro DNA repair in vivo and in vivo in relation to lung cancer at the N7-position of guanine of the ultimate carcinogen derived from benzo[a]pyrene. Chem Biol Interact 24: 345–353.

55. Liao M, He H, Kelley MR, Georgiadis MM (2007) Relative impact of nucleotide and copy number variation on gene expression phenotype. BMC Bioinformatics 11: 600.

56. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR (2009) The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 12: 1247–1269.

57. Manvila BA, Varney KM, Drohat AC (2010) Chemical shift assignments for benzo[a]pyrene diol-epoxide adducts bound to DNA. Carcinogenesis 31: 1180–1187.

58. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.

59. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.

60. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.

61. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.

62. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 15: 353–358.